China Knowledge is in the business of providing business solutions and products on China. Within the Group it has financial terminal, publishing, newswires, research, multimedia production and a wide range of consulting services offer to foreign businesses seeking opportunities in China.
Business · Manufacturing · Commercial & Professional Services
China’s specialty pharma firm CF PharmTech completed USD 90 mln Series E funding
2020/01/02 09:02:00
Pharmaceutical, Inhalation products, Funding

Jan 02, 2020 (China Knowledge) - China’s specialty pharmaceutical firm CF PharmTech has successfully raised RMB 630 mln (USD 90 mln) in its Series E funding round.

Founded in 2007, CF PharmTech is an independent specialty pharmaceutical company focused on the development and manufacturing of inhalation products for the treatments of asthma, COPD and allergic rhinitis. The company currently provides products such as HFA-based metered dose inhalers, nasal spray, nebulized and dry powder products for respiratory diseases. CF PharmTech aims to develop high-quality and affordable medicine to help patients achieve effective management care for respiratory diseases.

After the completion of the funding round, the company is expected to use the funds raised to continue its development of high-end and low-cost inhalation products for the international market.

In recent years, China has seen an increase in investments for high-potential and high-quality pharmaceutical companies within the country. The pharmaceutical companies in China has also began to focus beyond China into overseas market in order to capitalize on the rising demand for related products.

The latest funding round was led by investment firm New Alliance Capital.

Copyright © 2018

Send feedback or comments to:

For more news, financial weekly reports, business guides to China and other premium information, subscribe to China Knowledge today:

To access our page on Bloomberg, type CKFI